| A Phase III, Randomised, Double -Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure |
Ongoing |
Baxdrostat |
3 |
D6972C00003 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam),King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Riyadh) |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH) |
Ongoing |
Seralutinib |
3 |
GB002-3101 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| Long-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials |
Ongoing |
OAV101 (formerly AVXS-101) |
3 |
COAV101A12308 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours |
Ongoing |
BI 907828/ brigimadlin |
2 |
1403-0011 |
King Abdulaziz Medical City NG (Riyadh) |
| Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study |
Rejected |
BRENTUXIMAB VEDOTIN |
3 |
RJ19/119/J |
King Abdulaziz Medical City NG (Riyadh) |
| Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide |
Ongoing |
Talquetamab |
3 |
80202135EBF3001 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| The effect of novel D3 use as a mouthwash in COVID-19 patients |
Ongoing |
Cholecalciferol (vitamin D) |
3 |
2022-32 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension |
Ongoing |
Baxdrostat |
3 |
D6970C00009 |
King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER |
Ongoing |
Giredestrant , Phesgo |
3 |
WO43571 |
King Abdulaziz Medical City NG (Riyadh) , King Fahad Medical City (Riyadh),King Faisal Specialist Hospital and Research Center (Riyadh) |
| Modified Quadruple Therapy Regimen for Helicobacter pylori Eradication – A Prospective Randomized Controlled Trial |
Ongoing |
Bismuth Subcitrate Potassium , Tetracycline , Metronidazol |
2 |
2231295 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
